The role of biosimilar manufacturers in improving access to insulin globally

Lancet Diabetes Endocrinol. 2017 Aug;5(8):578. doi: 10.1016/S2213-8587(17)30218-8. Epub 2017 Jun 16.
No abstract available

Publication types

  • Letter

MeSH terms

  • Biosimilar Pharmaceuticals* / economics
  • Drug Industry* / economics
  • Global Health / economics
  • Health Services Accessibility / economics
  • Humans
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / economics
  • Insulin / therapeutic use*

Substances

  • Biosimilar Pharmaceuticals
  • Hypoglycemic Agents
  • Insulin